GTBP
NASD GT Biopharma Inc$6.21 ↑ +0.00 (+0.08%) Trading Up from the previous close of $6.20, $0.31 below the day’s high of $6.51
- YTD change
- -68.39%
- vs 20-day SMA
- -13.19%
- vs 200-day SMA
- -44.04%
Price ranges
Price & Performance
+5.75 (+1279.31%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 100.0% away from all-time highs of $470,475.00
- GTBP is down 68% since the beginning of the year
- GTBP is down 61% over the past 12 months
- GTBP is down 12% over the past 1 month
- 14% of all GTBP investors are betting against GTBP
GTBP reads poor: price sits below both the 20- and 200-day averages, the 12-month move is +870.4%.
- Previous minute
- +$0.00
- Last hour
- +$0.18
- Last 5 days
- -9.15%
- vs 8-day SMA
- -8.66%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of the immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product, GTB-3550, is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in San Francisco, CA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
